Previous close | 13.00 |
Open | 13.00 |
Bid | 15.90 |
Ask | 18.10 |
Strike | 40.00 |
Expiry date | 2024-05-17 |
Day's range | 13.00 - 13.00 |
Contract range | N/A |
Volume | |
Open interest | 19 |
Boston Scientific Corporation (NYSE: BSX) today announced positive six-month results from the ongoing pivotal MODULAR ATP clinical trial of the mCRM™ System,* the first modular cardiac rhythm management (CRM) system that consists of the EMBLEM™ Subcutaneous Implantable Defibrillator (S-ICD) System and the EMPOWER™ Leadless Pacemaker (LP). As components of the mCRM System, the devices are designed to work together wirelessly to coordinate painless intracardiac anti-tachycardia pacing (ATP) therap
Veeva (VEEV) announces the availability of Vault Basics for biotechs, which aims to deliver complete and pre-validated solutions for expanding businesses.
AxoGen (AXGN) starts the process of BLA submission to the FDA for the approval of its Avance Nerve Graft.